Portal:CPTAC
From WikiPathways
(Adding hallmark display) |
Current revision (09:21, 6 October 2019) (view source) |
||
| (6 intermediate revisions not shown.) | |||
| Line 9: | Line 9: | ||
}} | }} | ||
| - | <div style="float:left; width: | + | <div style="float:left; width:73%"> <!-- This width add to the the margin below to equal 99% --> |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 34: | Line 23: | ||
</div> | </div> | ||
| - | <div style="float:right; width: | + | <div style="float:right; width:26%"> <!-- This margin should be right of the above --> |
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 46: | Line 35: | ||
}} | }} | ||
| + | {{{{FULLPAGENAME}}/box-normal | ||
| + | |<!-- TITLE OF BOX --> | ||
| + | <big>''Assay Portal''</big> | ||
| + | |<!-- EDIT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | |<!-- CONTENT LINK --> | ||
| + | {{FULLPAGENAME}}/AssayPortal | ||
| + | | | ||
| + | }} | ||
| + | |||
| + | {{{{FULLPAGENAME}}/box-normal | ||
| + | |<!-- TITLE OF BOX --> | ||
| + | <big>''Pathway Curation''</big> | ||
| + | |<!-- EDIT LINK --> | ||
| + | {{FULLPAGENAME}}/Curation | ||
| + | |<!-- CONTENT LINK --> | ||
| + | {{FULLPAGENAME}}/Curation | ||
| + | | | ||
| + | }} | ||
{{{{FULLPAGENAME}}/box-normal | {{{{FULLPAGENAME}}/box-normal | ||
| Line 57: | Line 65: | ||
}} | }} | ||
</div> | </div> | ||
| + | |||
| + | [[Category:Portals]] | ||
Current revision
CPTAC Pathways
Welcome to the CPTAC Pathway PortalThis portal highlights pathway content relevant to the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The National Cancer Institute, part of the National Institutes of Health, announced the launch of a Clinical Proteomic Tumor Analysis Consortium in August 2011. CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer. To achieve this goal in a scientifically rigorous manner, the NCI launched CPTAC to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public. The pathways included in this portal have been organized into classic cancer hallmark categories, based on the different biological capabilities acquired during the multistep development of human tumors. To read more, see Hallmarks of cancer: the next generation, Hanahan and Weinberg, Cell 2011. | 
|
Cancer Hallmark Categories
| Sustaining proliferative signaling
MET in type 1 papillary renal cell carcinoma (Homo sapiens) Image does not exist MET in type 1 papillary renal cell carcinoma | Evading growth suppressors
G1 to S cell cycle control (Homo sapiens) Image does not exist G1 to S cell cycle control | Activating invasion and metastasis
MFAP5-mediated ovarian cancer cell motility and invasiveness (Homo sapiens) Image does not exist MFAP5-mediated ovarian cancer cell motility and invasiveness |
| Enabling replicative immortality
lncRNA in canonical Wnt signaling and colorectal cancer (Homo sapiens) Image does not exist lncRNA in canonical Wnt signaling and colorectal cancer | Inducing angiogenesis
Hedgehog signaling (Homo sapiens) Image does not exist Hedgehog signaling | Resisting cell death
TP53 network (Homo sapiens) Image does not exist TP53 network |
| Deregulating cellular energetics
Glycolysis and gluconeogenesis (Homo sapiens) Image does not exist Glycolysis and gluconeogenesis | Genome instability and mutation
DNA mismatch repair (Homo sapiens) Image does not exist DNA mismatch repair | Tumor promoting inflammation
Cytokines and inflammatory response (Homo sapiens) Image does not exist Cytokines and inflammatory response |
| Avoiding immune destruction
Interferon type I signaling (Homo sapiens) Image does not exist Interferon type I signaling | Therapeutics
NRF2-ARE regulation (Homo sapiens) Image does not exist NRF2-ARE regulation |
Featured Pathways
|
Image does not exist PDGFR-beta pathway Zhang, et al. Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer |
| View featured pathways |
| List of all pathways for this portal |
Assay Portal
CPTAC also includes an Assay Portal to widely disseminate highly characterized proteomic assays to the global research community, with access to SOPs, reagents, and assay characterization/validation data
Resources
- Over 2400 protein and peptide assays: Browse assays
- Over 750 antibodies and antigen targets: Browse antibodies
- Hundreds of terabytes of data sets: Browse data
Learn how they incorpated WikiPathways images with custom links on their site.
Pathway Curation
On this page you see rotating displays of hallmark and featured pathways. Where did these pathways come from? They came from people like you! The CPTAC set of pathways can be edited, fixed and added to using the pathway drawing and annotation tools here at WikiPathways.
Getting Started
- Introduction to WikiPathways (slides)
- WikiPathways Overview or New Contributor Quickstart
- General help pages
- CPTAC Workshop Exercises
Resources
- Learn more about CPTAC
- Pathway analysis
- Cytoscape and the WikiPathways app
- PathVisio and the WikiPathways plugin
Curation projects
- Curating Hallmark Pathways -- How to
- Example: construction of Pathways in Renal Cancer
- Contact Alex Pico if interested in curating, adding or using CPTAC pathways, apico@gladstone.ucsf.edu
